Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mycobacterium vaccae
- Development stage
- Phase 4
- Lead developer
- Immune Network
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral, Injectable
01
Overview
Mycobacterium vaccae is a non-pathogenic, saprophytic environmental bacterium used as an immunotherapeutic agent. It is typically administered as a whole-cell, heat-killed vaccine or oral tablet. The drug acts primarily by modulating immune responses—specifically, it induces regulatory T cells and shifts T-helper cell activity to reduce inappropriate Th2 responses and promote Th1-type immunity. This immunomodulatory effect has been investigated for adjunctive treatment of tuberculosis (including multidrug-resistant TB), atopic dermatitis, asthma, and other inflammatory conditions. Its anti-inflammatory properties are also being explored for stress resilience and prevention of allergic airway inflammation[1][3][4][5][6]. Mycobacterium vaccae-based products have received orphan drug status in the US for tuberculosis[8].
- Brand names
- V-7 ImmunitorV7 ImmunitorV 7 ImmunitorTubivac
- Other names
- mycobacterium vaccaeheat-inactivated mycobacterium vaccae pill
Beyond the preview
Go deeper on mycobacterium vaccae.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mycobacterium vaccae.